The Dixie Group Inc. (NASDAQ:DXYN) on Wednesday reported a loss of $528,000 in its fourth quarter. The Chattanooga, Tennessee-based company said it had a loss of 3 cents per share. Earnings, adjusted for non-recurring costs and to account for discontinued operations, came to less than 1 cent on a per-share basis. The floor covering company posted revenue of $107.8 million in the period.
The Dixie Group, Inc. (NASDAQ:DXYN) belongs to Industrial Goods sector. Its net profit margin is -1.70% and weekly performance is -11.22%. On last trading day company shares ended up at $3.72.
Gilead Sciences, Inc. (NASDAQ:GILD) announced results from a preclinical study conducted in collaboration with researchers at Beth Israel Deaconess Medical Center evaluating a proprietary investigational oral toll-like receptor 7 (TLR7) agonist, GS-9620, and a related molecular analogue, GS-986, as part of an HIV eradication strategy. Data from the study conducted in simian immunodeficiency virus (SIV)-infected virally suppressed rhesus macaques on antiretroviral therapy (ART) demonstrate that TLR7 agonist treatment induced transient plasma SIV RNA blips and reduced SIV DNA.
Gilead Sciences Inc. (NASDAQ:GILD) shares moved up 1.14% in last trading session and ended the day at $89.36. GILD Gross Margin is 87.70% and its return on assets is 40.20%. Gilead Sciences Inc. (NASDAQ:GILD) quarterly performance is -15.76%.
Weingarten Realty Investors (NYSE:WRI) declared an increase in the common dividend to $0.365 per share for the first quarter of 2016. This represents a 5.8% increase, resulting in an annualized dividend of $1.46 per share. The dividend is payable in cash on March 15, 2016 to shareholders of record on March 8, 2016.
On 24 February, Weingarten Realty Investors (NYSE:WRI) shares moved down -0.06% and was closed at $35.16. WRI EPS growth in last 5 year was 60.30%. Weingarten Realty Investors (NYSE:WRI) year to date (YTD) performance is 1.68%.
Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has approved XELJANZ® XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX). XELJANZ XR is the first and only once-daily oral RA treatment in its class, known as Janus kinase (JAK) inhibitors.
Pfizer Inc. (NYSE:PFE) ended the last trading day at $30.02. Company weekly volatility is calculated as 1.67% and price to cash ratio as 8.97. Pfizer Inc. (NYSE:PFE) showed a weekly performance of 1.32%.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced it has awarded the company’s 2016 Cystic Fibrosis (CF) Circle of Care grants, totaling approximately $1 million, to 18 non-profit medical, academic, patient and community organizations. In its second year, the grants fund innovative programs to help the cystic fibrosis community. CF is a rare, life-threatening genetic disease affecting approximately 75,000 people in North America, Europe and Australia.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares moved up 1.75% in last trading session and ended the day at $86.77. VRTX Gross Margin is 88.60% and its return on assets is -23.50%. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) quarterly performance is -33.54%.